



Supplementary Results, National Pancreatic Cancer Audit (NPACA) State of the Nation Report September 2025

Supplementary Figure 1. Percentage of people with stage 4 pancreatic cancer diagnosed in England during 2021-22 who received a form of disease-targeted treatment (surgery, chemotherapy, radiotherapy), by performance status and age	1
Supplementary Figure 2. Annual results by performance indicator for England, by year of diagnosis. 2	
Supplementary Figure 3. 90-day survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2021 and 31 December 2022 in England	3
Supplementary Figure 4. 1-year survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2021 and 31 December 2022 in England	4

Supplementary Figure 1. Percentage of people with stage 4 pancreatic cancer diagnosed in England during 2021-22 who received a form of disease-targeted treatment (surgery, chemotherapy, radiotherapy), by performance status and age




Supplementary Figure 2. Annual results by performance indicator for England, by year of diagnosis



Note: Indicator 1 (FDG-PET/CT scan before surgery) is not reported as the audit did not receive the Diagnostic Imaging Dataset (DIDs), which contains information on FDG-PET/CT, in time for inclusion in the analyses; Indicator 10 (90-day and 1-year survival from diagnosis) is presented in multi-year periods in Supplementary Figures 3 & 4. PI: Performance Indicator

Supplementary Figure 3. 90-day survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2021 and 31 December 2022 in England



Supplementary Figure 4. 1-year survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2021 and 31 December 2022 in England

